OS Therapies Incorporated
OSTX
$2.42
$0.093.86%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 876.99% | 574.51% | 254.13% | 23.96% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 377.93% | 184.93% | 56.91% | 1.59% | -- |
| Operating Income | -377.93% | -184.93% | -56.91% | -1.59% | -- |
| Income Before Tax | -121.18% | -52.64% | -14.00% | 17.15% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -121.18% | -52.64% | -14.00% | 17.15% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.18% | -52.64% | -14.00% | 17.15% | -- |
| EBIT | -377.93% | -184.93% | -56.91% | -1.59% | -- |
| EBITDA | -375.03% | -185.21% | -56.99% | -1.65% | -- |
| EPS Basic | 24.65% | 31.31% | 21.88% | 35.86% | -- |
| Normalized Basic EPS | 32.58% | 37.64% | 28.97% | 35.60% | -- |
| EPS Diluted | 24.65% | 31.31% | 21.88% | 35.86% | -- |
| Normalized Diluted EPS | 32.58% | 37.64% | 28.97% | 35.60% | -- |
| Average Basic Shares Outstanding | 200.05% | 137.28% | 57.22% | 24.90% | -- |
| Average Diluted Shares Outstanding | 200.05% | 137.28% | 57.22% | 24.90% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |